3-Hydroxy-N-propyl-piperidin | 27361-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-Hydroxy-N-propyl-piperidin
• 英文别名: 1-propyl-piperidin-3-ol；N-n-Propyl-3-hydroxy-piperidin；3-Hydroxy-1-propylpiperidine；1-propylpiperidin-3-ol
• CAS: 27361-79-1
• 化学式: C₈H₁₇NO
• mdl: MFCD16153145
• 分子量: 143.229
• InChiKey: AZQRDHDQFFRTTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-Hydroxy-N-propyl-piperidin 在 三甲基氨基磺酸 、 二甲基亚砜 、 三乙胺 作用下， 反应 12.0h， 以213 mg的产率得到1-丙基-3-哌啶酮
  参考文献：
  名称：

  Design and synthesis of Rho kinase inhibitors (I)

  摘要：

  Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.02.025
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 、 溶剂黄146 作用下， 生成 3-Hydroxy-N-propyl-piperidin
  参考文献：
  名称：

  Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1946, p. 385,387

  摘要：

  DOI：

文献信息

• 4-Phenylamino-quinazolin-6-yl-amides
  申请人：Fakhoury Alan Stephen

  公开号：US20050250761A1

  公开（公告）日：2005-11-10

  This invention provides quinazoline compounds of the formula: wherein: R 1 is halo; R 2 is H or halo; R 3 is a) C 1 -C 3 alkyl, optionally substituted by halo; or b) —(CH 2 ) n -morpholino, —(CH 2 ) n -piperidine, —(CH 2 ) n -piperazine, —(CH 2 ) n —-piperazine-N(C 1 -C 3 alkyl), —(CH 2 ) n -pyrrolidine, or —(CH 2 ) n -imidazole; n is 1 to 4; R 4 is —(CH 2 ) m -Het; Het is morpholine, piperidine, piperazine, piperazine-N(C 1 -C 3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH 2 , NH(C 1 -C 3 alkyl) or N (C 1 -C 3 alkyl) 2 ; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

  这项发明提供了式子为的喹唑啉化合物：其中：R1是卤素；R2是H或卤素；R3是a）C1-C3烷基，可选择地被卤素取代；或b）—（CH2）n-吗啉基、—（ ）n-哌啶基、—（ ）n-哌嗪基、—（ ）n-哌嗪-N（C1-C3烷基）、—（ ）n-吡咯烷基或—（ ）n-咪唑基；n为1至4；R4是—（ ）m-Het；Het是吗啉、哌啶、哌嗪、哌嗪-N（C1-C3烷基）、咪唑、吡咯烷、环庚烷、3,4-二氢-2H-吡啶或3,6-二氢-2H-吡啶，每个可选择地被烷基、卤素、OH、NH2、NH（C1-C3烷基）或N（C1-C3烷基）2取代；m为1-3；X为O、S或NH；或其药学上可接受的盐，以及用于制备它们的过程和中间化合物，有用的药用组合物和使用这些化合物治疗增生性疾病的方法。
• [EN] COMPOUNDS FOR USE IN STABILISING p53 MUTANTS<br/>[FR] COMPOSÉS PERMETTANT DE STABILISER LES MUTANTS DE P53
  申请人：MEDICAL RES COUNCIL

  公开号：WO2012175962A1

  公开（公告）日：2012-12-27

  Provided are compounds for use in a method of treatment of a subject who has a lesion or a tumour in which p53 carries a Y220C mutation, in which the compound is selected from compounds of the following formula (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof: (I) R: where A is CR4 or N; -R-1 is selected from -OH, -OMe, -NH2, -SH, -F and -CF3; -R2 is selected from -CI, -Br, -I, and ethynyl (-C≡CH); -R3 is selected from -I, -Br, -CI, ethynyl (-C≡CH), -R35, -H, -OMe, and -N02; wherein -R3S is selected from: and -R5 is selected from -COOH and: 8A formula Ilia formula 1Mb formula 111 o 3 where -R6, -R7A, - R7B, -Rs, and -R8A are as defined in the specification. Compounds of formula (I) are also provided, as is their use in methods of treatment, and methods for their preparation.

  提供了用于治疗患有p53携带Y220C突变的病变或肿瘤的方法中使用的化合物，其中该化合物从以下公式(I)的化合物中选择，并且其药学上可接受的盐、水合物和溶剂化合物：(I) R：其中A为CR4或N；-R-1选择自-OH、-OMe、-NH2、-SH、-F和-CF3；-R2选择自-Cl、-Br、-I和乙炔（-C≡CH）；-R3选择自-I、-Br、-Cl、乙炔（-C≡CH）、-R35、-H、-OMe和-N02；其中-R3S选择自：和-R5选择自-COOH和：8A公式Ilia公式1Mb公式111 o 3其中-R6、-R7A、-R7B、-Rs和-R8A如规范中所定义。还提供了公式(I)的化合物，以及它们在治疗方法中的使用和制备方法。
• Nicotinamide Derivatives
  申请人：Crawforth James Michael

  公开号：US20110306597A1

  公开（公告）日：2011-12-15

  The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions.

  本发明涉及公式(I)的化合物及其药学上可接受的盐和溶剂，其中取代基在此定义，以及包含这种化合物的组合物，以及这种化合物用于治疗过敏和呼吸系统疾病的用途。
• Heteroaryl Dihydroindolones as Kinase Inhibitors
  申请人：Boral Sougato

  公开号：US20110257238A1

  公开（公告）日：2011-10-20

  The present invention provides a compound represented by the formula: wherein the variables R 1 , b, R 6 , Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.

  本发明提供的化合物由以下式子表示：其中变量R1、b、R6、Y、Z、X、R和a在规范中定义。所述化合物可用于治疗与未调节的酪氨酸激酶信号传导相关的疾病的方法，其中所述疾病选自癌症、血管增生性疾病、纤维性疾病、系膜细胞增生性疾病和代谢性疾病等组。
• KINASE INHIBITORS
  申请人：Allergan, Inc.

  公开号：US20130267497A1

  公开（公告）日：2013-10-10

  The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

  本发明涉及药物输送系统，包括眼内植入物，其中包括有机分子，能够调节酪氨酸激酶信号传导，以调节、调节和/或抑制异常细胞增殖，与聚合物结合，该聚合物用于控制、修改、调节和/或减缓治疗成分进入放置该复合物的眼部环境中的释放。